IB Net Payout Yields Model

Aurora Cannabis: Conflicting Moment

Aurora Cannabis reported solid FQ4 preliminary numbers including a move towards positive EBITDA.
Health Canada data doesn't support these healthy numbers with industry inventory levels soaring.
The company likely only sold 50% of inventory available for sale.
The $7 billion market cap is not a relative value in the cannabis sector.
Before the open on August 6, Aurora Cannabis (ACB) updated the market with a positive pre-announcement on FQ4 results for the period ending in June. Apparently, the company remains on track to positive adjusted EBITDA targets by reaching revenue growth not supported by Health Canada sales data. Investors are urged to remain cautious on the stock with mounting cannabis inventories in the Canadian market over shadowing short-term results.
Read the full article on Seeking Alpha.

Disclosure: No position mentioned. Please review the disclaimer page for more details. 


Popular posts from this blog

Aurora Cannabis: Deal Or No Deal

Celsius: Unaltered Growth Story

Hims & Hers Health: Still Firing On Strong Cylinders